Technology - Germany



Hold (old: Hold) 08.02.2024

EUR 1.60 (old: EUR 1.60)

Positive outlook after a challenging 2023

Topic: Singulus looks back at a difficult FY23 due to project postponements and cyclical weakness. Nevertheless, there is sun behind the clouds and FY24e looks more promising.

During the first 9M of FY23, the **Solar segment** showed weakness in order intake due to postponements of larger projects. However, Singulus most important customer CNBM intends to expand the production capacity of cadmium telluride (CdTe) thin-film solar modules and Singulus already received initial orders. First deliveries are expected for Q1 FY24e in China, with follow-up orders being likely. Additionally, Singulus is **relocating the final assembly** of some machines from Europe to China in cooperation with CNBM to save transportation costs, while product development remains in Germany. Sales in the solar segment are expected to come in at € 56.9m for FY24e (eNuW: + 31.4% yoy).

Life science revenues were soft during FY23e (eNuW: -53% yoy) caused by a weak economic environment. The situation should remain challenging during FY24e, as global GDP growth is projected by the IMF to stay unchanged at 3.1% in 2024, which is below the historical (2000-19) average of 3.8%. On a positive note, on January 31st, Singulus announced the sale of a POLYCOATER machine to a leading Italian packaging specialist in the cosmetic industry. We expect life science revenue in FY24e to come in at € 26.3m (eNuW: + 9.6% yoy).

The **semiconductor** business showed a positive development in the recent quarters. Singulus has expanded the available portfolio of production modules, which can be connected to the central handling system and now addresses a variety of applications, such as µLED, RDL and metallization. By **entering the larger µLED market**, Singulus has a fair chance of creating enough revenue to cover its fixed costs. While revenue contribution of magnetic sensors is already strong, we expect the new µLED business to show meaningful results at earliest in FY25e (eNuW). Sales in the semiconductor segment should come in at the lower double-digit range for FY24e (eNuW: € 11.8m).

Solvency remains an issue. With c. € 44m in debt of which € 30m are effectively from CNBM as of 9M FY23, the company is highly dependent on CNBM. Due to the volatile nature of its project business, visibility as to when the company can sustainably surpass the necessary sales threshold to generate positive earnings remains low. Reiterate HOLD with an unchanged PT of € 1.60 based on DCF.

Y/E 31.12 (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	29.5	68.7	87.8	76.8	95.0	99.8
Sales growth	-62.8%	132.9%	27.8%	-12.5%	23.7%	5.0%
EBITDA	-25.9	-8.6	9.4	-5.6	0.2	2.0
Net debt (if net cash=0)	21.1	1.3	3.3	23.8	34.3	41.9
FCF	-0.3	23.2	-24.7	-17.5	-7.5	-4.5
Net Debt/EBITDA	-0.8	-0.2	0.4	-4.2	183.1	20.8
EPS pro forma	-3.38	-1.60	-0.01	-1.29	-0.65	-0.43
EBITDA margin	-87.8%	-12.5%	10.7%	-7.3%	0.2%	2.0%
ROCE	-88.9%	-45.9%	31.3%	-256.1%	-30.3%	-6.4%
EV/sales	1.8	0.5	0.3	0.6	0.6	0.7
EV/EBITDA	-2.1	-3.8	3.2	-8.8	321.1	33.7
PER	-0.5	-1.1	-155.7	-1.4	-2.7	-4.1
Adjusted FCF yield	-54.3%	-58.8%	5.5%	-17.3%	-4.6%	-0.9%


Source: Company data, NuWays, Close price as of 06.02.2024

2022

2023e

2024e

2025e



Company description

2021

2020

Source: NuWays Research

Sales (2020-25e)

100.0m

75.0m

50.0m

25.0m

0.0m

SINGULUS TECHNOLOGIES develops and manufactures innovative machines and systems for production processes in thin-film technology and surface treatment in the photovoltaic, semiconductor, medical technology, packaging, glass and automotive, battery and hydrogen markets.




Market data					
Share price (in €)	1.50				
Market cap (in € m)	15.6				
Number of shares (in m pcs)	8.9				
Enterprise value (in € m)	60.2				
Ø trading volume (6 months)	11,100				

IC	ientifier
Bloomberg	SNG GR
Reuters	SNGG
WKN	A1681X
ISIN	DE000A1681X5

Ney Shareholders	
Triumph Group	16.8%
Universal	10.2%
Clemens Jakopitsch	6.2%
Free Float	66.9%

Estimates changes					
	<u>2023e</u>	<u>2024e</u>	<u>2025e</u>		
Sales	0%	0%	0%		
EBIT	0%	0%	0%		
EPS	0%	0%	0%		

Comment on changes



Guidance

ROCE (2020-25e)

- FY23 Sales: € 90-100m
- FY23 EBIT: low single-digit € m

Update - 08.02.2024



Financials

Profit and loss (EUR m)	2020	2021	2022	2023e	2024e	2025e
Sales	29.5	68.7	87.8	76.8	95.0	99.8
Sales growth	-62.8%	132.9%	27.8%	-12.5%	23.7%	5.0%
Cost of sales	35.0	50.6	62.6	57.3	69.4	72.3
Gross profit	-5.5	18.1	25.2	19.5	25.7	27.4
Sales and marketing	10.3	11.0	11.7	10.3	12.4	12.0
General and administration	10.1	11.2	10.5	10.2	10.5	10.5
Research and development	10.1	8.1	7.1	7.1	6.8	6.8
Other operating income	5.9	0.5	13.2	0.6	1.9	2.0
Other operating expenses	0.6	0.7	3.2	1.3	0.7	0.7
Total operating expenses	25.2	30.5	19.3	28.3	28.5	28.0
Unusual or infrequent items	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	-25.9	-8.6	9.4	-5.6	0.2	2.0
Depreciation	4.8	3.8	1.8	2.0	1.8	1.4
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.0	0.0	1.7	1.2	1.2	1.2
Impairment charges	6.1	0.0	0.0	0.0	0.0	0.0
EBIT (inc revaluation net)	-36.8	-12.4	5.9	-8.8	-2.8	-0.6
Interest income	0.0	0.9	0.0	0.0	0.0	0.0
Interest expenses	2.1	1.7	2.0	2.7	3.0	3.2
Investment income	0.0	0.0	0.0	0.0	0.0	0.0
Financial result	-2.1	-0.8	-2.0	-2.7	-3.0	-3.2
Recurring pretax income from continuing operations	-38.9	-13.2	3.9	-11.5	-5.8	-3.8
Extraordinary income/loss	0.0	0.0	0.0	0.0	0.0	0.0
Earnings before taxes	-38.9	-13.2	3.9	-11.5	-5.8	-3.8
Income tax expense	-2.7	1.0	4.0	-0.1	0.0	0.0
Net income from continuing operations	-36.2	-14.2	-0.1	-11.4	-5.8	-3.8
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0
Net income	-36.2	-14.2	-0.1	-11.4	-5.8	-3.8
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0
,						
Net profit (reported)	-36.2	-14.2	-0.1	-11.4	-5.8	-3.8
	-36.2 8.9	-14.2 8.9	-0.1 8.9	-11.4 8.9	-5.8 8.9	
Net profit (reported)						8.9
Net profit (reported) Average number of shares EPS reported	8.9 -4.07	8.9 -1.60	8.9 -0.01	8.9 -1.29	8.9 -0.65	8.9 -0.43
Net profit (reported) Average number of shares EPS reported Profit and loss (common size)	8.9 - 4.07	8.9 -1.60 2021	8.9 -0.01 2022	8.9 -1.29 2023e	8.9 -0.65 2024e	8.9 -0.43 2025e
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales	8.9 -4.07 2020 100.0%	8.9 -1.60 2021 100.0%	8.9 -0.01 2022 100.0%	8.9 -1.29 2023e 100.0%	8.9 -0.65 2024e 100.0%	8.9 -0.43 2025e 100.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales	8.9 -4.07 2020 100.0% 118.6%	8.9 -1.60 2021 100.0% 73.7%	8.9 -0.01 2022 100.0% 71.3%	8.9 -1.29 2023e 100.0% 74.7%	8.9 -0.65 2024e 100.0% 73.0%	8.9 -0.43 2025e 100.0% 72.5%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit	8.9 -4.07 2020 100.0% 118.6% -18.6%	8.9 -1.60 2021 100.0% 73.7% 26.3%	8.9 -0.01 2022 100.0% 71.3% 28.7%	8.9 -1.29 2023e 100.0% 74.7% 25.3%	8.9 -0.65 2024e 100.0% 73.0% 27.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 34.2%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5% 6.8%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 34.2% 20.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5% 6.8% 2.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses	8.9 -4.07 100.0% 118.6% -18.6% 34.9% 34.2% 34.2% 20.0% 2.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5% 6.8% 2.0% 0.7%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 34.2% 20.0% 2.0% 85.4%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 0.2%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 2.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 0.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 0.0% 20.7%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0% 0.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net)	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0% -18.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0% -18.0% 1.3%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0% -18.0% 1.3% 2.5%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% 3.5%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% 3.5% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0%	8.9 -0.43 2025e 100.0% 72.5% 12.0% 10.5% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2% 0.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1% 0.0% neg.	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0% neg.	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0% neg.	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% 3.5% 0.0% neg.	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0% neg.	8.9 -0.43 2025e 100.0% 72.5% 12.0% 10.5% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% neg.
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1% 0.0% neg131.9%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 0.0% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0% neg19.2%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0% neg. 4.4%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% 3.5% 0.0% neg15.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0% neg6.1%	8.9 -0.43 2025e 100.0% 72.5% 12.0% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2% 0.0% neg3.8%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1% 0.0% neg131.9% 0.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 0.0% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0% neg19.2% 0.0%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0% neg. 4.4% 0.0%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% a.5% 0.0% neg15.0% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0% neg6.1% 0.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2% 0.0% neg3.8% 0.0%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1% 0.0% neg131.9% 0.0%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 0.0% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0% neg19.2% 0.0% -19.2%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0% neg. 4.4% 0.0% 4.4%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% a.5% 0.0% neg15.0% 0.0% -15.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0% neg6.1%	8.9 -0.43 2025e 100.0% 72.5% 12.0% 10.5% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2% 0.0% neg3.8% 0.0% -3.8%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1% 0.0% neg131.9% 6.9%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0% neg19.2% -7.6%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0% neg. 4.4% 0.0% 4.4% 102.6%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% a.5% 0.0% neg15.0% 0.0% -15.0% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0% neg6.1% 0.0%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2% 0.0% neg3.8% 0.0% -3.8%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1% 0.0% neg131.9% 6.9% -122.7%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0% neg19.2% -7.6% -20.7%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0% neg. 4.4% 0.0% 4.4% 102.6% -0.1%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% neg15.0% 0.0% -15.0% 0.0% -14.9%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0% neg6.1% 0.0% -6.1%	8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2% 0.0% neg3.8% 0.0% -3.8%
Net profit (reported) Average number of shares EPS reported Profit and loss (common size) Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses Total operating expenses Unusual or infrequent items EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate	8.9 -4.07 2020 100.0% 118.6% -18.6% 34.9% 34.2% 20.0% 2.0% 85.4% 0.0% -87.8% 16.3% 0.0% 20.7% -124.7% 0.0% 7.1% 0.0% neg131.9% 6.9%	8.9 -1.60 2021 100.0% 73.7% 26.3% 16.0% 16.3% 11.8% 0.7% 1.0% 44.4% 0.0% -12.5% 5.5% 0.0% 0.0% -18.0% 1.3% 2.5% 0.0% neg19.2% -7.6%	8.9 -0.01 2022 100.0% 71.3% 28.7% 13.3% 12.0% 8.1% 15.0% 3.6% 22.0% 0.0% 10.7% 2.1% 0.0% 1.9% 0.0% 6.7% 0.0% 2.3% 0.0% neg. 4.4% 0.0% 4.4% 102.6%	8.9 -1.29 2023e 100.0% 74.7% 25.3% 13.4% 13.3% 9.2% 0.8% 1.7% 36.8% 0.0% -7.3% 2.6% 0.0% 1.6% 0.0% -11.5% 0.0% a.5% 0.0% neg15.0% 0.0% -15.0% 0.0%	8.9 -0.65 2024e 100.0% 73.0% 27.0% 13.0% 11.1% 7.2% 2.0% 0.8% 30.0% 0.0% 1.9% 0.0% 1.3% 0.0% -3.0% 0.0% 3.2% 0.0% neg6.1% 0.0%	-3.8 8.9 -0.43 2025e 100.0% 72.5% 27.5% 12.0% 10.5% 6.8% 2.0% 0.7% 28.1% 0.0% 1.4% 0.0% 1.2% 0.0% -0.6% 0.0% 3.2% 0.0% -3.8% 0.0% -3.8% 0.0% -3.8% 0.0%

-122.7%

-20.7%

Net profit (reported)
Source: Company data, NuWays

NuWays AG 2

-0.1%

-14.9%

-6.1%

-3.8%

Update - 08.02.2024



Balance sheet (EUR m)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	12.5	11.6	11.7	11.5	11.5	11.5
Property, plant and equipment	12.0	10.0	6.7	5.4	4.3	3.5
Financial assets	4.8	15.1	3.8	4.1	4.1	4.1
FIXED ASSETS	29.3	36.7	22.2	21.0	19.9	19.1
Inventories	8.4	13.5	14.0	13.7	17.3	18.1
Accounts receivable	10.8	17.9	22.8	29.5	31.7	33.2
Other assets and short-term financial assets	0.0	0.0	0.0	0.0	0.0	0.0
Liquid assets	9.8	15.0	18.7	10.0	9.5	12.0
Deferred taxes	0.2	0.2	0.1	0.1	0.1	0.1
Deferred charges and prepaid expenses	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT ASSETS	29.2	46.6	55.6	53.3	58.6	63.4
TOTAL ASSETS	58.5	83.3	77.8	74.3	78.5	82.5
SHAREHOLDERS EQUITY	-27.3	-39.7	-33.6	-48.0	-56.8	-63.6
MINORITY INTEREST	0.0	0.0	0.0	0.0	0.0	0.0
Provisions for pensions and similar obligations	17.0	15.4	11.4	10.3	10.3	10.3
Other provisions and accrued liabilities	6.2	7.6	10.1	10.4	10.4	10.4
Short-term liabilities to banks	4.0	0.0	10.0	0.0	10.0	20.0
Accounts payable	6.5	16.9	9.9	12.8	15.8	16.6
Advance payments received on orders	2.7	5.6	8.0	5.0	5.0	5.0
Other liabilities (incl. from lease and rental contracts)	21.4	59.0	44.7	44.7	44.7	44.7
Deferred taxes	0.6	1.9	4.8	4.8	4.8	4.8
Deferred income	0.0	0.0	0.0	0.0	0.0	0.0
CURRENT LIABILITIES	30.6	81.5	62.6	62.5	65.5	66.3
TOTAL LIABILITIES AND SHAREHOLDERS EQUITY	58.5	83.3	77.8	74.3	78.5	82.5
Balance sheet (common size)	2020	2021	2022	2023e	2024e	2025e
Intangible assets	21.4%	13.9%	15.0%	15.5%	14.6%	13.9%
Property, plant and equipment	20.5%	12.0%	8.6%	7.3%	5.5%	4.2%
Financial assets	8.2%	18.1%	4.9%	5.5%	5.2%	5.0%
FIXED ASSETS	50.1%	44.1%	28.5%	28.3%	25.3%	23.1%
Inventories	14.4%	16.2%	18.0%	18.4%	22.1%	21.9%
Accounts receivable	18.5%	21.5%	29.3%	39.8%	40.3%	40.3%
Other assets and short-term financial assets	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Liquid assets	16.8%	18.0%	24.0%	13.5%	12.1%	14.5%
Deferred taxes	0.3%	0.2%	0.1%	0.1%	0.1%	0.1%
Deferred charges and prepaid expenses	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT ASSETS	49.9%	55.9%	71.5%	71.7%	74.7%	76.9%
TOTAL ASSETS	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
SHAREHOLDERS EQUITY	-46.7%	-47.7%	-43.2%	-64.6%	-72.3%	-77.1%
MINORITY INTEREST	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Provisions for pensions and similar obligations	29.1%	18.5%	14.7%	13.9%	13.1%	12.5%
Other provisions and accrued liabilities	10.6%	9.1%	13.0%	13.9%	13.1%	12.5%
Short-term liabilities to banks	6.8%	0.0%	12.9%	0.0%	12.7%	24.2%
Accounts payable	11.1%	20.3%	12.7%	17.2%	20.2%	20.1%
Advance payments received on orders	4.6%	6.7%	10.3%	6.7%	6.4%	6.1%
Other liabilities (incl. from lease and rental contracts)	36.6%	70.8%	57.5%	60.2%	56.9%	54.2%
Deferred taxes	1.0%	2.3%	6.2%	6.5%	6.1%	5.8%
Deferred income	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CURRENT LIABILITIES	52.3%	97.8%	80.5%	84.1%	83.5%	80.4%

Source: Company data, NuWays

Update - 08.02.2024



Cash flow statement (EUR m)	2020	2021	2022	2023e	2024e	2025e
Net profit/loss	-36.2	-14.2	-0.1	-11.4	-5.8	-3.8
Depreciation of fixed assets (incl. leases)	4.8	3.8	1.8	2.0	1.8	1.4
Amortisation of goodwill & intangible assets	0.0	0.0	1.7	1.2	1.2	1.2
Others	-1.9	-11.7	10.9	-3.0	-3.0	-3.0
Cash flow from operating activities	-2.1	20.3	-26.2	-19.0	-8.6	-5.3
Increase/decrease in inventory	7.1	-5.1	-0.5	0.3	-3.7	-0.7
Increase/decrease in accounts receivable	6.0	-7.1	-4.9	-6.7	-2.1	-1.6
Increase/decrease in accounts payable	-1.8	10.4	-7.0	2.9	3.0	0.8
Increase/decrease in other working capital positions	0.1	2.9	2.4	-3.0	0.0	0.0
Increase/decrease in working capital	11.4	1.1	-10.0	-6.5	-2.8	-1.5
Cash flow from operating activities	2.7	24.1	-22.7	-15.8	-5.6	-2.7
CAPEX	3.0	0.9	2.0	1.7	1.9	1.8
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	9.3	0.0	0.0	0.0
Cash flow from investing activities	-3.0	-0.9	7.3	-1.7	-1.9	-1.8
Cash flow before financing	-0.3	23.2	-15.4	-17.5	-7.5	-4.5
Increase/decrease in debt position	-2.6	-6.6	8.0	11.9	10.0	10.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.0
Others	-1.9	-11.7	10.9	-3.0	-3.0	-3.0
Effects of exchange rate changes on cash	-0.2	0.3	0.2	0.0	0.0	0.0
Cash flow from financing activities	-4.5	-18.3	18.9	8.9	7.0	7.0
Increase/decrease in liquid assets	-5.0	5.2	3.7	-8.7	-0.5	2.5
Liquid assets at end of period	9.8	15.0	18.7	10.0	9.5	12.0
Enquire accord at one or portor	0.0	1010			0.0	12.0
Key ratios (EUR m)	2020	2021	2022	2023e	2024e	2025e
P&L growth analysis						
Sales growth	-62.8%	132.9%	27.8%	-12.5%	23.7%	5.0%
EBITDA growth	-384.6%	1128.6%	-136.3%	-34.4%	-98.0%	-135.6%
EBIT growth	-641.2%	51.2%	-116.0%	-28.7%	-147.7%	-93.3%
EPS growth	-4625.0%	25.7%	-99.7%	-19.4%	5712.5%	-66.9%
Efficiency						
Sales per employee	89.7	216.7	273.5	260.3	314.6	324.9
EBITDA per employee	-78.7	-27.1	29.3	-19.1	0.6	6.5
No. employees (average)	329	317	321	295	302	307
Balance sheet analysis						
Avg. working capital / sales	73.1%	22.1%	16.5%	22.3%	24.8%	27.6%
Inventory turnover (sales/inventory)	2.9	4.6	4.6	4.2	4.0	4.0
Accounts receivable turnover	2.1	4.8	4.3	2.6	3.0	3.0
Accounts payable turnover	4.0	5.9	6.6	6.0	6.0	6.0
Cash flow analysis						
Free cash flow	-0.3	23.2	-24.7	-17.5	-7.5	-4.5
Free cash flow/sales	-1.0%	33.7%	-28.1%	-22.8%	-7.9%	-4.5%
FCF / net profit	0.8%	neg.	24700.0%	153.2%	128.9%	119.4%
Capex / sales	10.2%	1.4%	2.3%	2.2%	2.0%	1.8%
Solvency						
Net debt	21.1	1.3	3.3	23.8	34.3	41.9
Net Debt/EBITDA	-0.8	-0.2	0.4	-4.2	183.1	20.8
Dividend payout ratio		0.0%	0.0%	0.0%	0.0%	0.0%
	0.0%					7.3%
	0.0% 8.6%		7.6%	10.8%	9.1%	
Interest paid / avg. debt Returns	8.6%	7.9%	7.6%	10.8%	9.1%	
Interest paid / avg. debt			7.6%	10.8% -256.1%	-30.3%	-6.4%
Interest paid / avg. debt Returns ROCE	-88.9%	7.9%	31.3%	-256.1%	-30.3%	
Interest paid / avg. debt Returns ROCE ROE	8.6% -88.9% n.a.	7.9% -45.9% n.a.	31.3% n.a.	-256.1% n.a.	-30.3% n.a.	n.a.
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield	8.6% -88.9% n.a. -54.3%	7.9% -45.9% n.a. -58.8%	31.3% n.a. 5.5%	-256.1% n.a. -17.3%	-30.3% n.a. -4.6%	n.a. -0.9%
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield	8.6% -88.9% n.a. -54.3% 0.0%	7.9% -45.9% n.a. -58.8% 0.0%	31.3% n.a. 5.5% 0.0%	-256.1% n.a. -17.3% 0.0%	-30.3% n.a. -4.6% 0.0%	n.a. -0.9% 0.0%
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS	8.6% -88.9% n.a. -54.3% 0.0% 0.0	7.9% -45.9% n.a. -58.8% 0.0% 0.0	31.3% n.a. 5.5% 0.0% 0.0	-256.1% n.a. -17.3% 0.0% 0.0	-30.3% n.a. -4.6% 0.0% 0.0	n.a. -0.9% 0.0% 0.0
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported	8.6% -88.9% n.a. -54.3% 0.0% 0.0 -4.07	7.9% -45.9% n.a. -58.8% 0.0% 0.0 -1.60	31.3% n.a. 5.5% 0.0% 0.0	-256.1% n.a. -17.3% 0.0% 0.0 -1.29	-30.3% n.a. -4.6% 0.0% 0.0	n.a. -0.9% 0.0% 0.0 -0.43
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares	8.6% -88.9% n.a. -54.3% 0.0% 0.0	7.9% -45.9% n.a. -58.8% 0.0% 0.0	31.3% n.a. 5.5% 0.0% 0.0	-256.1% n.a. -17.3% 0.0% 0.0	-30.3% n.a. -4.6% 0.0% 0.0	n.a. -0.9% 0.0% 0.0
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios	8.6% -88.9% n.a54.3% 0.0% 0.0 -4.07 8.9	7.9% -45.9% n.a58.8% 0.0% 0.0 -1.60 8.9	31.3% n.a. 5.5% 0.0% 0.0 -0.01 8.9	-256.1% n.a. -17.3% 0.0% 0.0 -1.29 8.9	-30.3% n.a. -4.6% 0.0% 0.0 -0.65 8.9	n.a. -0.9% 0.0% 0.0 -0.43 8.9
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV	8.6% -88.9% n.a54.3% 0.0% 0.0 -4.07 8.9	7.9% -45.9% n.a58.8% 0.0% 0.0 -1.60 8.9	31.3% n.a. 5.5% 0.0% 0.0 -0.01 8.9	-256.1% n.a. -17.3% 0.0% 0.0 -1.29 8.9	-30.3% n.a. -4.6% 0.0% 0.0 -0.65 8.9	n.a. -0.9% 0.0% 0.0 -0.43 8.9
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV EV/sales	8.6% -88.9% n.a54.3% 0.0% 0.0 -4.07 8.9 -0.6 1.8	7.9% -45.9% n.a58.8% 0.0% 0.0 -1.60 8.9 -0.4 0.5	31.3% n.a. 5.5% 0.0% 0.0 -0.01 8.9	-256.1% n.a. -17.3% 0.0% 0.0 -1.29 8.9 -0.3 0.6	-30.3% n.a. -4.6% 0.0% 0.0 -0.65 8.9	n.a. -0.9% 0.0% 0.0 -0.43 8.9 -0.2
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV EV/sales EV/EBITDA	8.6% -88.9% n.a54.3% 0.0% 0.0 -4.07 8.9 -0.6 1.8 -2.1	7.9% -45.9% n.a58.8% 0.0% 0.0 -1.60 8.9 -0.4 0.5 -3.8	31.3% n.a. 5.5% 0.0% 0.0 -0.01 8.9 -0.5 0.3	-256.1% n.a. -17.3% 0.0% 0.0 -1.29 8.9 -0.3 0.6 -8.8	-30.3% n.a. -4.6% 0.0% 0.0 -0.65 8.9 -0.3 0.6 321.1	n.a0.9% 0.0% 0.0 -0.43 8.9 -0.2 0.7 33.7
Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV EV/sales	8.6% -88.9% n.a54.3% 0.0% 0.0 -4.07 8.9 -0.6 1.8	7.9% -45.9% n.a58.8% 0.0% 0.0 -1.60 8.9 -0.4 0.5	31.3% n.a. 5.5% 0.0% 0.0 -0.01 8.9	-256.1% n.a. -17.3% 0.0% 0.0 -1.29 8.9 -0.3 0.6	-30.3% n.a. -4.6% 0.0% 0.0 -0.65 8.9	n.a. -0.9% 0.0% 0.0 -0.43 8.9 -0.2

Update - 08.02.2024



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

Company	Disclosures
Singulus Technologies AG	2

Historical target price and ratin	g changes for Singulus T	echnologies AG			
Company	Date	Analyst	Rating	Target Price	Close
Singulus Technologies AG	15.11.2023	Wunderlich, Tim	Hold	EUR 1.60	EUR 1.76
	01.11.2023	Wunderlich, Tim	Hold	EUR 1.90	EUR 1.73
	15.08.2023	Wunderlich, Tim	Hold	EUR 2.90	EUR 2.37
	10.02.2023	Wunderlich, Tim	Under Review	n.a.	EUR 1.93

Update - 08.02.2024



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed companies:

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 08/02/2024 07:57 AM

Date of publication dissemination: 08/02/2024 07:57 AM

Update - 08.02.2024



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow

Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

Instagram



Twitter/X



<u>Linkedlı</u>

